Linking costs and survival in the treatment of older adults with chronic myeloid leukemia

Medical Care

Volumn 54, Issue 4, 2016, Pages 380-385

  Lin, Pei Jung ^a   Winn, Aaron N ^b   Parsons, Susan K ^a   Neumann, Peter J ^a   Weiss, Elisa S ^c   Cohen, Joshua T ^a  

^a TUFTS MEDICAL CENTER   (United States)

^b University of North Carolina at Chapel Hill   (United States)

^c The Leukemia & Lymphoma Society   (United States)

Author keywords

chronic myeloid leukemia; cost effectiveness analysis; health care costs; survival

Indexed keywords

IMATINIB; ANTINEOPLASTIC AGENT;

AGED; ARTICLE; CANCER REGISTRY; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; FEMALE; HEALTH CARE COST; HOSPICE CARE; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MEDIAN SURVIVAL TIME; MEDICAL FEE; MEDICARE; OUTPATIENT CARE; PRIORITY JOURNAL; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; KAPLAN MEIER METHOD; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MORTALITY; QUALITY ADJUSTED LIFE YEAR; STATISTICS AND NUMERICAL DATA; TRENDS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LIFE EXPECTANCY; MALE; MEDICARE; QUALITY-ADJUSTED LIFE YEARS; SEER PROGRAM; UNITED STATES;

EID: 84954348819     PISSN: 00257079     EISSN: 15371948     Source Type: Journal    
DOI: 10.1097/MLR.0000000000000496     Document Type: Article

References (48)

1. Lee SJ, Anasetti C, Kuntz KM, et al. The costs and cost-effectiveness of unrelated donor bone marrow transplantation for chronic phase chronic myelogenous leukemia. Blood. 1998; 92: 4047-4052
2. Gambacorti-Passerini C, Antolini L, Mahon FX, et al. Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. J Natl Cancer Inst. 2011; 103: 553-561
3. Kantarjian H, OBrien S. The chronic leukemias. In: Goldman L, Schafer A, Arend W, et al, eds. Cecil Medicine, 24th ed. Philadelphia, PA: Elsevier Saunders; 2012: 1209-1218
4. Experts in Chronic Myeloid Leukemia. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts. Blood. 2013; 121: 4439-4442
5. Goldman DP, Philipson T. Five myths about cancer care in America. Health Affairs. 2014; 33: 1801-1804
6. Meropol NJ, Schrag D, Smith TJ, et al. American Society of Clinical Oncology guidance statement: the cost of cancer care. J Clin Oncol. 2009; 27: 3868-3874
7. Dusetzina SB, Winn AN, Abel GA, et al. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia. J Clin Oncol. 2014; 32: 306-311
8. Ramsey SD. How should we pay the piper when hes calling the tune? On the long-Term affordability of cancer care in the United States. J Clin Oncol. 2007; 25: 175-179
9. Darkow T, Maclean R, Joyce GF, et al. Coverage and use of cancer therapies in the treatment of chronic myeloid leukemia. Am J Manag Care. 2012; 18: S272-S278
10. Gratwohl A, Brand R, Apperley J, et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-Term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica. 2006; 91: 513-521
11. Porter ME. What is value in health care? N Engl J Med. 2010; 363: 2477-2481
12. Katz SJ. Valuing cancer care: challenges and opportunities. J Oncol Pract. 2013; 9: 114-115
13. Chambers JD, Thorat T, Pyo J, et al. Despite high costs, specialty drugs may offer value for money comparable to that of traditional drugs. Health Affairs. 2014; 33: 1751-1760
14. American Society of Clinical Oncology. The state of cancer care in America, 2014: a report by the American Society of Clinical Oncology. J Oncol Pract. 2014; 10: 119-142
15. Greenberg D, Earle C, Fang CH, et al. When is cancer care costeffective? A systematic overview of cost-utility analyses in oncology. J Natl Cancer Inst. 2010; 102: 82-88
16. Breitscheidel L. Cost utility of allogeneic stem cell transplantation with matched unrelated donor versus treatment with imatinib for adult patients with newly diagnosed chronic myeloid leukaemia. J Med Econ. 2008; 11: 571-584
17. Dalziel K, Round A, Garside R, et al. Cost effectiveness of imatinib compared with interferon-Alpha or hydroxycarbamide for first-line treatment of chronic myeloid leukaemia. Pharmacoeconomics. 2005; 23: 515-526
18. Reed SD, Anstrom KJ, Li Y, et al. Updated estimates of survival and cost effectiveness for imatinib versus interferon-Alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics. 2008; 26: 435-446
19. Reed SD, Anstrom KJ, Ludmer JA, et al. Cost-effectiveness of imatinib versus interferon-Alpha plus low-dose cytarabine for patients with newly diagnosed chronic-phase chronic myeloid leukemia. Cancer. 2004; 101: 2574-2583
20. Skrepnek GH, Ballard EE. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-Analytic approach. Pharmacotherapy. 2005; 25: 325-334
21. Yin W, Penrod JR, Maclean R, et al. Value of survival gains in chronic myeloid leukemia. Am J Manag Care. 2012; 18: S257-S264
22. Ohm L, Lundqvist A, Dickman P, et al. Real-world cost-effectiveness in chronic myeloid leukemia: the price of success during four decades of development from non-Targeted treatment to imatinib. Leuk Lymphoma. 2015; 56: 1385-1391
23. Lakdawalla DN, Sun EC, Jena AB, et al. An economic evaluation of the war on cancer. J Health Econ. 2010; 29: 333-346
24. Sun EC, Jena AB, Lakdawalla DN, et al. The contributions of improved therapy and early detection to cancer survival gains, 1988-2000. Forum Health Econ Policy. 2010; 13: Article 1
25. Philipson T, Eber M, Lakdawalla DN, et al. An analysis of whether higher health care spending in the United States versus Europe is worth it in the case of cancer. Health Affairs. 2012; 31: 667-675
26. SEER. Site Recode ICD-O-3 Definition. Available at: http://seer. cancer.gov/siterecode/icdo3-d01272003/. Accessed December 30, 2013
27. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383
28. Klabunde CN, Potosky AL, Legler JM, et al. Development of a comorbidity index using physician claims data. J Clin Epidemiol. 2000; 53: 1258-1267
29. Benner JS, Glynn RJ, Mogun H, et al. Long-Term persistence in use of statin therapy in elderly patients. JAMA. 2002; 288: 455-461
30. Gray AM, Clarke PM, Wolstenholme J, et al. Applied Methods of Costeffectiveness Analysis in Healthcare. New York: Oxford University Press; 2010
31. Newhouse JP. Medical Care Price Indices: Problems and Opportunities. NBER Working Paper No. 8168; 2001
32. Mariotto AB, Yabroff KR, Shao Y, et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst. 2011; 103: 117-128
33. Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010; 170: 537-542
34. Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006; 6: 52-58
35. Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract. 2011; 7: 25s-30s
36. Warren JL, Brown ML, Fay MP, et al. Costs of treatment for elderly women with early-stage breast cancer in fee-for-service settings. J Clin Oncol. 2002; 20: 307-316
37. Wijeysundera HC, Wang X, Tomlinson G, et al. Techniques for estimating health care costs with censored data: an overview for the health services researcher. Clinicoecon Outcomes Res. 2012; 4: 145-155
38. Manning WG, Basu A, Mullahy J. Generalized modeling approaches to risk adjustment of skewed outcomes data. J Health Econ. 2005; 24: 465-488
39. Conti R, Berndt ER. Firm Entry, Exit and Price Competition in the Market for Multisource Specialty Drugs, 2006-2012. NBER Book Series Studies in Income and Wealth: Measuring and Modeling Health Care Costs; 2013
40. Litchtenberg F, Duflos G. The Effect of Patient Expiration on US Drug Prices, Marketing and Utilization by the Public. Medical Progress Report No 11: Manhattan Institute2009
41. Basu A, Rathouz PJ. Estimating marginal and incremental effects on health outcomes using flexible link and variance function models. Biostatistics. 2005; 6: 93-109
42. Breslow N. Covariance analysis of censored survival data. Biometrics. 1974; 30: 89-99
43. Kleinman LC, Norton EC. Whats the risk? A simple approach for estimating adjusted risk measures from nonlinear models including logistic regression. Health Serv Res. 2009; 44: 288-302
44. Weinstein MC, Siegel JE, Gold MR, et al. Recommendations of the panel on cost-effectiveness in health and medicine. JAMA. 1996; 276: 1253-1258
45. Polsky D, Glick HA, Willke R, et al. Confidence intervals for costeffectiveness ratios: a comparison of four methods. Health Econ. 1997; 6: 243-252
46. Anderson KR, Chambers CR, Lam N, et al. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia. J Oncol Pharm Pract. 2015; 21: 19-25
47. Vander Velde N, Chen L, Guo A, et al. Study of imatinib treatment patterns and outcomes among US veteran patients with Philadelphia chromosome-positive chronic myeloid leukemia. J Oncol Pract. 2013; 9: e212-e219
48. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness-The curious resilience of the 50, 000-per-QALY threshold. N Engl J Med. 2014; 371: 796-797